BMRN stock forecast
Our latest prediction for BioMarin Pharmaceutical, Inc.'s stock price was made on the April 8, 2019 when the stock price was at 92.38$.
In the short term (2weeks), BMRN's stock price should outperform the market by 0.73%. During that period the price should oscillate between -4.30% and +4.94%.
In the medium term (3months), BMRN's stock price should outperform the market by 2.00%. During that period the price should oscillate between -10.43% and +15.84%.Get email alerts
About BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its products include Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim. The company was founded by Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
At the moment the company generates 1603M USD in revenues.
On its last earning announcement, the company reported a loss of -0.24$ per share.
The book value per share is 16.25$
Three months stock forecastApril 8, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|